Taxotere Articles
Ontario MoH To Pay For R-PRs Taxotere
23 September 1996
R-PR Posts Profits Climb But Flat Turnover In First Half
5 August 1996
R-PR's Taxotere Receives Nine More Approvals
15 July 1996
R-PR Launches Taxotere In USA
17 June 1996
Taxotere Cleared For Marketing In USA
20 May 1996
USA To Adopt Fast-Track For Cancer Drugs
8 April 1996
EMEA 1995-95: A Crucial Period of Transition
25 March 1996
Taxotere In France
26 February 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
EMEA Reports Successes In Inaugural 1995
5 February 1996
Docetaxel Shows Efficacy In Ovarian Cancer
5 February 1996
Rhone-Poulenc Rorer's "Year Of Firsts"
5 February 1996
Rhone-Poulenc Rorer's Taxotere: approval and launch news
29 January 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Taxotere Study Looks At Operable Breast Cancer
29 January 1996
R-PR: Taxotere news
22 January 1996
EU CPMP December Plenary Meeting
8 January 1996
R-PR's Share Price
18 December 1995
R-PR Starts Fisons R&D Integration; Product Update
4 December 1995
Taxotere Gets EU-Wide Approval For Breast Cancer
4 December 1995
Taxotere In Head & Neck Cancer
20 November 1995
Rhone-Poulenc Rorer: Taxotere news
6 November 1995
Patent Row Breaks Out Over Taxoid Drugs
30 October 1995
Taxotere Clears Major Marketing Hurdle In USA
23 October 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
...And Taxotere In Third Market, Canada
25 September 1995
NEW YORK STOCK COMMENT
7 August 1995
Third Approval For R-PR's Taxotere
31 July 1995
R-PR Looks To New Products For Growth
20 February 1995
R-PR's Irinotecan And Colorectal Cancer
13 February 1995
Search For Growth Drivers At Rhone-Poulenc Rorer
13 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
1994 Transitional For R-PR With Better Second Half
6 February 1995
Polarization Concerns For Chemical/Drug Majors?
16 January 1995
Corporate News In Brief
2 January 1995
NEW YORK STOCK COMMENT
2 January 1995
European Stock Comment
19 December 1994
NEW YORK STOCK COMMENT
19 December 1994
Taxotere Not Recommended For Approval In USA
19 December 1994
Docetaxel Approved In First Market
12 December 1994
Taxotere Trials Expanded
7 November 1994
FDA To Review Taxotere
31 October 1994
Taxotere Effective In Breast Cancer
17 October 1994
Taxotere Submission In USA, Canada And EU
8 August 1994
R-PR FILES TAXOTERE NDA IN JAPAN
30 May 1994
TAXOTERE REVEALS BROAD ACTIVITY
23 May 1994
R-PR REGROUPS BIOTECH ACTIVITY
9 May 1994
NEW TRIAL DATA ON R-PR'S TAXOTERE
21 March 1994
OUTLOOK UNCERTAIN AT RHONE-POULENC IN 1994
28 February 1994
TAXOL LAUNCHED AT HIGH PRICE IN FRANCE
21 February 1994
RHONE-POULENC RORER BID FOR OTC DRUG LINK UP
10 January 1994
EC'S CPMP BACKS TAXOL APPROVAL
27 September 1993
RHONE-POULENC: A TRANSFORMATION
16 August 1993
RHONE-POULENC STARTS NEW TAXOTERE TRIALS
12 July 1993
PHASE II RESULTS WITH R-PR'S TAXOTERE
7 June 1993
RHONE-POULENC RORER'S FOCUSED R&D PIPELINE
7 June 1993
EDATREXATE COMBINATIONS IN CANCER
31 May 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
RHONE-POULENC RORER SALES $4 BILLION IN 1992
8 February 1993
B-M SQUIBB SETS US TAXOL PRICE
18 January 1993
NEW CANCER DRUGS SHINE AT US MEETING
2 November 1992
RHONE-POULENC RORER NET INCOME UP 13.4%
2 November 1992
RHONE-POULENC RORER REVIEWS DRUG PRIORITIES
5 October 1992
R-PR TO CODEVELOP TAXOTERE IN JAPAN
1 June 1992
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
